Full Press Release Details
CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL ), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive Officer, will present at the Canaccord Genuity 42 nd Annual Growth Conference on Wednesday, August 10, 2022 , at 4:00 p.m. ET in Boston .
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com , and archived for 30 days following the presentation.
SOURCE Nuvalent, Inc.